NEW YORK (GenomeWeb) – Tataa Biocenter today announced it has signed an exclusive agreement to license the French Institute for Health and Medical Research's (INSERM) ValidPrime qPCR assay correction technology.

ValidPrime is a tool used to measure and compensate for the genomic DNA background signal in qPCR-based gene expression measurements. The technology "accurately corrects all reactions in high-throughput qPCR BioMark arrays for signals derived from gDNA," Vlasta Korenkova, head of Tataa's Prague facility, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.